Compare Abeona Therapeutics Inc (ABEO) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $12.57. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | MSTZ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $27.92 |
52-Week Low | $4.17 | $3.12 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MSTZ trades at $11.08, down 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10, resistance at $12. Financial ratios are unavailable, limiting fundamental assessment. Recent ETF-focused news mentions Strategy Inc. but provides no direct MSTZ updates, leaving a data gap for current company performance.
Outlook is cautious due to bearish technicals and lack of fundamental data. Investment opportunity hinges on forthcoming financial disclosures to clarify valuation and profitability. Primary risks include undefined business metrics and potential market volatility. Investors await earnings reports for clearer direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
